Canada · Delayed Price · Currency is CAD Metro Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw 4.1% sales growth to CAD 5.1B, with strong pharmacy and discount banner performance, and adjusted EPS up 8.8%. Gross margin improved, online sales rose nearly 20%, and a Québec strike is expected to impact Q3.
-
Q1 saw 3.3% sales growth and 5.5% adjusted EPS growth, despite a costly freezer disruption. Food and pharmacy segments both posted positive same-store sales, with discount and online channels outperforming. Dividend was raised 10.1% and share buybacks continued.
Fiscal Year 2025
-
Q4 saw 3.4% sales growth and 8.6% higher adjusted net earnings, despite a CAD 22.5 million after-tax impact from a Toronto freezer shutdown. Discount and pharmacy segments led growth, with strong online and private label performance. FY 2026 guidance includes higher CapEx and continued store expansion.
-
Q3 saw 3.3% sales growth, 5.7% EBITDA growth, and a 12.6% rise in adjusted EPS, with strong pharmacy and discount banner performance. Gross margin and productivity improved, while inflation and tariffs remain key risks. Online sales and store expansions contributed to growth.
-
Second quarter sales rose 5.5% to $4.9B, with strong growth in both food and pharmacy. Adjusted EPS increased 12.1% to $1.02, and online sales grew 26%. Management maintains an 8%-10% EPS growth target despite ongoing macroeconomic and tariff uncertainties.
-
First quarter sales rose 2.9% to CAD 5.12 billion, with adjusted net earnings up 4.4% and EPS up 7.8%. Online sales grew 18%, and the company maintained its 8%-10% EPS growth target, while dividend and share repurchases continued.
-
The meeting reviewed strong financial results, supply chain modernization, and digital growth, with all board nominees and proposals from management approved. Shareholder engagement led to ongoing hybrid meetings and a commitment to AI governance. Dividend growth continued for the 31st year.
Fiscal Year 2024
-
Q4 sales reached CAD 4.94B, with food and pharmacy same-store sales up 2.2% and 5.7%, respectively. Gross margin and EBITDA improved, and supply chain modernization was completed. Fiscal 2025 targets include 2%-4% sales growth and 8%-10% EPS growth, with continued investment in store expansion and loyalty programs.
-
Sales rose 3.5% to CAD 6.65B, with stable gross margin and strong discount and pharmacy growth. Distribution center automation is ramping up, and the Moi Rewards program is driving engagement. CapEx is on track, and leverage remains low.